Ado-trastuzumab emtansine (T-DM1) in patients (pts) with HER2 amplified (amp) tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the National Cancer Institute (NCI) Molecular Analysis for Therapy Choice (MATCH) trial.

被引：21

作者：

Jhaveri, Komal L.

Makker, Vicky

Wang, Xin Victoria

Chen, Alice P.

Flaherty, Keith

Conley, Barbara A.

O'Dwyer, Peter J.

Williams, Paul M.

Hamilton, Stanley R.

Harris, Lyndsay

McShane, Lisa

Rubinstein, Lawrence

Gray, Robert James

Li, Shuli

Mitchell, Edith P.

Patton, David

Moscow, Jeffrey

Zwiebel, James A.

Arteaga, Carlos L.

Luoh, Shiuh-Wen

机构：

[1] NYU, Canc Inst, New York, NY USA

[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[3] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA

[4] NCI, NIH, Early Clin Trials Dev Program, DCTD, Bethesda, MD 20892 USA

[5] Massachusetts Gen Hosp, Boston, MA 02114 USA

[6] NCI, Rockville, MD USA

[7] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[8] Frederick Natl Lab Canc Res, Frederick, MD USA

[9] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[10] NCI, Canc Diag Program, Rockville, MD USA

[11] NCI, Bethesda, MD 20892 USA

[12] Dana Farber Canc Inst, Boston, MA 02115 USA

[13] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA

[14] NCI, Ctr Biomed Informat & Informat Technol, Rockville, MD USA

[15] J457 Kentucky Clin, Lexington, KY USA

[16] Canc Therapy Evaluat Program, Bethesda, MD USA

[17] Vanderbilt Univ, Ingram Canc Ctr, 221 Kirkland Hall, Nashville, TN 37235 USA

[18] Oregon Hlth & Sci Univ, Lake Oswego, OR USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.100

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

100

引用

页数：1